Overview

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma.
Phase:
Phase 3
Details
Lead Sponsor:
MediQuest Therapeutics
Treatments:
Nitroglycerin